

References – Gleevec

1. Gleevec Product Monograph, September 19, 2001, and August 7, 2002.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 2001 Apr 5;344(14):1031-7.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 2001 Apr 5;344(14):1038-42.
4. Talpaz M, et al. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. 42nd Annual Meeting of the American Society of Hematology, Dec.1-5, 2000, San Francisco, Ca. (abstract).
5. Kantarjian H, et al. A phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive myeloid leukemia. 42nd Annual Meeting of the American Society of Hematology, Dec.1-5, 2000, San Francisco, Ca. (abstract).
6. Sawyers C, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis. 42nd Annual Meeting of the American Society of Hematology, Dec.1-5, 2000, San Francisco, Ca. (abstract).
7. Ottmann OG, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias. 42nd Annual Meeting of the American Society of Hematology, Dec.1-5, 2000, San Francisco, Ca. (abstract).
8. Mauro MJ, Druker BL. STI571: Targeting BCR-ABL as therapy for CML. *Onco* 2001;6:233-8.
9. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. *Blood* 2001 Oct 1;98(7):2039-42.
10. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous Leukemia. *JAMA* 2001;256(8):895-898.
11. CancerNet – Chronic Myelogenous Leukemia. <http://cancernet.nci.nih.gov>
12. Cancer Care Ontario Practice Guidelines Initiative – Drug Therapy for Chronic Myeloid Leukemia (Practice Guideline No.6-3). http://hiru.mcmaster.ca/ccopgi/guidelines/hem/cpg6_3f.html
13. Kantarjian H, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Enj J Med* 2002; 346(9):645-652.
14. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *NEJM* 2002;347(7):472-80.